Innovative Gene Therapy Trial For Parkinson’s Disease

Innovative Gene Therapy Trial For Parkinson’s Disease

A trial for a new gene therapy, known as AXO-Lenti-PD, aimed at improving the supply of dopamine in the brains of people with Parkinson’s disease has been launched by researchers at UCL and University College London Hospital. In people affected by Parkinson’s disease, parts of the brain become progressively damaged over many years, resulting in motor symptoms including tremor, rigidity, and bradykinesia (slowness of movement). The trial will assess up to 30 patients with PD from UCLH, the National Hospital for Neurology and Neurosurgery (NHNN), London, Cambridge University Hospital and the Henri Mondor Hospital, Paris.

READ FULL STORY